Mizuho initiated coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a report released on Tuesday morning, TipRanks reports. The brokerage issued a buy rating and a $38.00 price target on the biotechnology company’s stock.
Several other analysts also recently commented on ATRA. Zacks Investment Research raised shares of Atara Biotherapeutics from a hold rating to a buy rating and set a $9.50 target price for the company in a report on Thursday, May 7th. BidaskClub raised shares of Atara Biotherapeutics from a sell rating to a hold rating in a report on Wednesday, March 25th. JPMorgan Chase & Co. lifted their target price on shares of Atara Biotherapeutics from $22.00 to $23.00 and gave the stock a neutral rating in a report on Tuesday, May 12th. Canaccord Genuity reaffirmed a buy rating on shares of Atara Biotherapeutics in a report on Tuesday, February 18th. Finally, Citigroup upgraded shares of Atara Biotherapeutics from a neutral rating to a buy rating and set a $14.00 price objective for the company in a research note on Thursday, April 23rd. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. Atara Biotherapeutics presently has a consensus rating of Buy and an average price target of $27.17.
Shares of ATRA opened at $14.81 on Tuesday. The company has a market cap of $841.25 million, a PE ratio of -2.71 and a beta of 2.14. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.27 and a quick ratio of 7.27. The firm has a 50-day moving average of $9.10 and a 200-day moving average of $12.35. Atara Biotherapeutics has a one year low of $4.52 and a one year high of $24.75.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported ($1.20) EPS for the quarter, topping the consensus estimate of ($1.41) by $0.21. Analysts expect that Atara Biotherapeutics will post -4.72 earnings per share for the current year.
In other news, insider Joe Newell sold 2,740 shares of the business’s stock in a transaction that occurred on Friday, March 27th. The shares were sold at an average price of $9.17, for a total value of $25,125.80. Following the completion of the transaction, the insider now directly owns 126,141 shares in the company, valued at approximately $1,156,712.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 5,224 shares of company stock valued at $47,096 in the last quarter. Corporate insiders own 7.00% of the company’s stock.
Several large investors have recently modified their holdings of the company. Redmile Group LLC raised its position in shares of Atara Biotherapeutics by 13.9% in the 1st quarter. Redmile Group LLC now owns 5,293,370 shares of the biotechnology company’s stock valued at $45,047,000 after buying an additional 644,800 shares in the last quarter. Maverick Capital Ltd. raised its position in shares of Atara Biotherapeutics by 4.9% in the 1st quarter. Maverick Capital Ltd. now owns 5,199,897 shares of the biotechnology company’s stock valued at $44,251,000 after buying an additional 241,466 shares in the last quarter. Morgan Stanley raised its position in shares of Atara Biotherapeutics by 18.1% in the 1st quarter. Morgan Stanley now owns 3,462,329 shares of the biotechnology company’s stock valued at $29,463,000 after buying an additional 529,482 shares in the last quarter. Bridger Management LLC raised its position in shares of Atara Biotherapeutics by 10.2% in the 4th quarter. Bridger Management LLC now owns 2,932,865 shares of the biotechnology company’s stock valued at $48,304,000 after buying an additional 271,845 shares in the last quarter. Finally, Federated Hermes Inc. raised its position in shares of Atara Biotherapeutics by 26.5% in the 1st quarter. Federated Hermes Inc. now owns 2,889,541 shares of the biotechnology company’s stock valued at $24,590,000 after buying an additional 605,068 shares in the last quarter.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Article: Gross Domestic Product (GDP)
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.